DIVISION OF HEALTH CARE FINANCING AND POLICY

NEVADA MEDICAID

DRUG USE REVIEW (DUR) BOARD PROPOSED PRIOR AUTHORIZATION CRITERIA

Suboxone® (buprenorphine/naloxone) and Subutex® (buprenorphine) are a covered benefit of Nevada Medicaid for recipients who meet the following criteria for coverage.

1. Coverage and Limitations:

Authorization will be given if the following criteria are met and documented:

Requests for Suboxone® (buprenorphine/naloxone)

- 1. Must have ALL of the following:
 - a. The recipient has a diagnosis of opioid dependence.

AND

The recipient is 16 years of age or older.

AND

The medication is being prescribed by a physician with a Drug Addiction Treatment Act (DATA) of 2000 waiver who has a unique "X" DEA number.

AND

There is documentation (name of specific substance abuse program) that formal substance abuse counseling/treatment is in place or, if the prescriber is a psychiatrist or certified addiction specialist, they may confirm that they personally render the counseling.

AND

There is documentation that the patient has honored all of their office visits and counseling sessions in a compliant manner.

Requests for Subutex® (buprenorphine)

- 2. Must have ALL of the following:
 - b. The recipient has a diagnosis of opioid dependence.

AND

The recipient is 16 years of age or older.

AND

The medication is being prescribed by a physician with a Drug Addiction Treatment Act (DATA) of 2000 waiver who has a unique "X" DEA number.

AND

There is documentation (name of specific substance abuse program) that formal substance abuse counseling/treatment is in place or, if the prescriber is a psychiatrist or certified addiction specialist, they may confirm that they personally render the counseling.

AND

There is documentation that the patient has honored all of their office visits and counseling sessions in a compliant manner.

AND

There is documentation that the recipient is pregnant.

OR

There is documentation the recipient is breastfeeding an infant who is dependent on methadone or morphine.





2. PA Guidelines:

Prior authorization approval will be for 1 year

3. Quantity Limitations:

Suboxone® 2 mg/0.5 mg sublingual tablet/film: 3 tablets/film per day Suboxone® 4 mg/1 mg sublingual film: 1 film per day Suboxone® 8 mg/2 mg sublingual tablet/film: 2 tablets/film per day Suboxone® 12 mg/3 mg sublingual tablet/film: 1 film per day Subutex® 8 mg sublingual tablet: 2 tablets per day Subutex® 2 mg sublingual tablet: 3 tablets per day



